COVID-19 prophylaxis with doxycycline and zinc in health care workers: a prospective, randomized, double-blind clinical trial
•Efficacy of doxycycline and zinc as potential treatment of SARS-CoV-2 infection is discussed.•SARS-CoV-2 contamination appeared to be reduced after treatment.•COVID-19 infection risk was not associated with other comorbidities.•The combined treatments of doxycycline and zinc have minimal side effec...
Saved in:
Published in: | International journal of infectious diseases Vol. 122; pp. 553 - 558 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Canada
Elsevier Ltd
01-09-2022
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •Efficacy of doxycycline and zinc as potential treatment of SARS-CoV-2 infection is discussed.•SARS-CoV-2 contamination appeared to be reduced after treatment.•COVID-19 infection risk was not associated with other comorbidities.•The combined treatments of doxycycline and zinc have minimal side effects.
This study aims to assess the efficacy of a combination treatment of doxycycline and zinc in the primary prevention of COVID-19 infection in Tunisian health care workers compared with two control groups.
We conducted a prospective, randomized, double-blind clinical trial over 5 months to determine the efficacy of a preventive combination treatment dose of doxycycline (100 mg/day) and zinc (15 mg/day), compared with a single-dose treatment with doxycycline versus placebo. The effectiveness of preventive treatment was measured by the significant decline in the number of cases of COVID-19 infection and/or a decrease in the viral load as determined by SARS-CoV-2 cycle threshold value using reverse transcription polymerase chain reaction tests.
We detected a significant decrease of SARS-CoV-2 infection in the group that received both doxycycline and zinc compared with other participants. We also demonstrated that COVID-19 infection was neither associated with diabetes (P = 0.51) nor associated with hypertension (P = 0.99), asthma (P = 0.52), and chronic obstructive pulmonary disease (P = 0.27).
Our findings indicated that preventive therapy reduced the risk of SARS-CoV-2. These results suggest that the combination of doxycycline and zinc has a protective effect in patients with SARS-CoV-2 infection. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ISSN: | 1201-9712 1878-3511 |
DOI: | 10.1016/j.ijid.2022.06.016 |